Improvements in renal osteodystrophy in patients treated with lanthanum carbonate for two years

Clinical Nephrology

Volumn 70, Issue 4, 2008, Pages 284-295

  Malluche, H H ^a   Siami, G A ^b   Swanepoel, C ^c   Wang, G H ^a   Mawad, H ^a   Confer, R D ^d   Smith, M ^d   Pratt, R D ^d   Monier Faugere, M C ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d SHIRE   (United States)

Author keywords

Bone; Dialysis; FOSRENOL; Lanthanum carbonate; Phosphorus

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; CALCIUM ACETATE; CALCIUM CARBONATE; LANTHANUM CARBONATE; OSTEOCALCIN; PHOSPHATE; PHOSPHATE BINDING AGENT; RENVELA; SEVELAMER; UNCLASSIFIED DRUG; VITAMIN D;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE BIOPSY; BONE MINERALIZATION; BONE TURNOVER; CALCIUM BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DOSE TITRATION; DRUG MEGADOSE; FEMALE; FOLLOW UP; HEMODIALYSIS PATIENT; HISTOPATHOLOGY; HUMAN; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; METABOLIC BONE DISEASE; MULTICENTER STUDY; OPEN STUDY; OSSIFICATION; OSTEOMALACIA; PHOSPHATE BLOOD LEVEL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RENAL OSTEODYSTROPHY; UNSPECIFIED SIDE EFFECT;

ADULT; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BONE REMODELING; CALCIUM; FEMALE; HUMANS; LANTHANUM; MALE; MIDDLE AGED; PARATHYROID HORMONE; PHOSPHORUS; PROSPECTIVE STUDIES; RENAL DIALYSIS; RENAL OSTEODYSTROPHY; TREATMENT OUTCOME;

EID: 54949133635     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Adragao T, Ferreira A, Frazao JM, Gil C, Oliveira C, Galvao J, Sarmento M, Ribeiro S, Dickson J, Carvalho B, Rodriguez I, Baldaia J, Pereira O, Faugere MC, Malluche HH. Vascular calcifications and bone turnover in hemodialysis patients. Nephrol Dial Transplant. 2006; 21 (Suppl 4): iv292.
2. Al-Baaj F, Speake M, Hutchison AJ. Control of serum phosphate by oral lanthanum carbonate in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis in a short-term, placebo-controlled study. Nephrol Dial Transplant. 2005; 20: 775-782.
3. Alfrey AC, LeGendre GR, Kaehny WD. The dialysis encephalopathy syndrome. Possible aluminum intoxication. N Engl J Med. 1976; 294: 184-188.
4. Asci G OM, Duman S, Toz H, Savas R, Kayikcioglu M, Celik G, Ozbek S, Basci A, Monier-Faugere MC, Malluche HH, Ok E. The link between cardiovascular and bone disease in hemodialysis patients. Nephrol Dial Transplant. 2007; 22 (Suppl 6): vi217.
5. Behets GJ, Dams G, Vercauteren SR, Damment SJ, Bouillon R, De Broe ME, D'Haese PC. Does the phosphate binder lanthanum carbonate affect bone in rats with chronic renal failure? J Am Soc Nephrol. 2004; 15: 2219-2228.
6. Behets GJ, Gritters M, Dams G, De Broe ME, D'Haese PC. Effects of efficient phosphate binding on bone in chronic renal failure rats. Ren Fail. 2005a; 27: 475-484.
7. Behets GJ, Verberckmoes SC, Oste L, Bervoets AR, Salome M, Cox A G, Denton J, De Broe ME, D'Haese PC. Localization of lanthanum, in bone of chronic renal failure rats after oral dosing with lanthanum carbonate. Kidney Int. 2005b; 67: 1830-1836.
8. Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E, Luft FC. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis. 1996; 27: 394-401.
9. Chiang SS, Chen JB, Yang WC. Lanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease. Clin Nephrol. 2005; 63: 461-470.
10. Coen G, Manni M, Addari O, Ballanti P, Pasquali M, Chicca S, Mazzaferro S, Napoletano I, Sardella D, Bonucci E. Metabolic acidosis and osteodystrophic bone disease in predialysis chronic renal failure: effect of calcitriol treatment. Miner Electrolyte Metab. 1995; 21: 375-382.
11. Damment SJP, Shen V. Assessment of effects of lanthanum carbonate with and without phosphate supplementation on bone mineralization in uremic rats. Clin Nephrol 2005; 63: 127-137.
12. Dent CE, Richens A, Rowe DJ, Stamp TC. Osteomalacia with long-term anticonvulsant therapy in epilepsy. Br Med J. 1970; 4: 69-72.
13. Denton J, Freemont AJ, Ball J. Detection and distribution of aluminum in bone. J Clin Pathol. 1984; 37: 136-142.
14. D'Haese PC, Spasovski GB, Sikole A, Hutchison A, Freemont TJ, Sulkova S, Swanepoel C, Pejanovic S, Djukanovic L, Balducci A, Coen G, Sulowicz W, Ferreira A, Torres A, Curic S, Popovic M, Dimkovic N, De Broe ME. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl. 2003; 63: 73-78.
15. Faugere MC, Arnala IO, Ritz E, Malluche HH. Loss of bone resulting from accumulation of aluminum in bone of patients undergoing dialysis. J Lab Clin Med. 1986; 107: 481-487.
16. Finn WF. Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients. Clin Nephrol 2006; 65: 191-202.
17. Finn WF, Joy MS, Hladik G. Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis. Clin Nephrol. 2004; 62: 193-201.
18. Freemont AJ, Hoyland JA, Denton J. The effects of lanthanum carbonate and calcium carbonate on bone abnormalities in patients with end-stage renal disease. Clin Nephrol. 2005; 64: 428-437.
19. Freemont T, Malluche HH. Utilization of bone histomorphometry in renal osteodystrophy: demonstration of a new approach using data from a prospective study of lanthanum carbonate. Clin Nephrol 2005; 63: 138-145.
20. Goldner J. A modification of the Masson trichrome technique for routine laboratory purposes. Am J Pathol. 1938; 14: 237-243.
21. Hutchison AJ, Maes B, Vanwalleghem J, Asmus G, Mohamed E, Schmieder R, Backs W, Jamar R, Vosskuhler A. Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate. Nephron Clin Pract. 2005; 100: c8-19.
22. Joy MS, Finn WF. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis. 2003; 42: 96-107.
23. Lillie PD, Fullmer HM. Histopathologic techniques and practical histochemistry. New York: McGraw Hill; 1976. p. 534-535.
24. London GM, Marty C, Marchais SJ, Guerin AP, Metivier F, de Vernejoul MC. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol. 2004; 15: 1943-1951.
25. Malluche HH, Faugere MC. Aluminum: toxin or innocent bystander in renal osteodystrophy. Am J Kidney Dis. 1985; 6: 336-341.
26. Malluche HH, Faugere MC. Atlas of Mineralized Bone Histology. New York: Karger; 1986. p. 26-36.
27. Malluche HH, Faugere MC. Aluminum-related bone disease. Blood Purif. 1999; 6: 1-15.
28. Malluche HH, Faugere MC, Smith AJ Jr, Friedler RM. Aluminum intoxication of bone in renal failure - fact or fiction? Kidney Int Suppl. 1986; 18: 70-73.
29. Malluche HH, Faugere MC, Wang G, Damment SJP, Webster I. No evidence of osteomalacia in dialysis patients treated with lanthanum carbonate up to 5 years. J Am Soc Nephrol. 2004; 15 Abstracts issue: 270A.
30. Malluche HH, Monier-Faugere MC. Risk of adynamic bone disease in dialyzed patients. Kidney Int Suppl. 1992; 38: S62-67.
31. Malluche HH, Monier-Faugere MC. Renal osteodystrophy: what's in a name? Presentation of a clinically useful new model to interpret bone histologic findings. Clin Nephrol. 2006; 65: 235-242.
32. Malluche HH, Ritz E, Lange HP Kutschera L, Hodgson M, Seiffert U, Schoeppe W. Bone histology in incipient and advanced renal failure. Kidney Int. 1976; 9: 355-362.
33. Malluche HH, Sherman D, Meyer W, Massry SG. A new semiautomatic method for quantitative static and dynamic bone histology. Calcif Tissue Int. 1982; 34: 439-448.
34. Manaka RC, Malluche HH. A program package for quantitative analysis of histologic structure and remodeling dynamics of bone. Comput Programs Biomed. 1981; 13: 191-201.
35. Melsen F, Mosekilde L. A quantitative analysis of bone changes following anticonvulsant therapy. Calcif Tissue Res. 1976; 21 (Suppl): 247-251.
36. Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006; 69: 1945-1953.
37. Monier-Faugere MC, Malluche HH. Trends in renal osteodystrophy: a survey from 1983 to 1995 in a total of 2,248 patients. Nephrol Dial Transplant. 1996; 11 Suppl 3: 111-120.
38. Parfitt AM. Osteomalacia and phenytoin therapy. Ann Intern Med. 1995; 122: 632.
39. Persy V, De Broe M, Ketteler M. Bisphosphonates prevent experimental vascular calcification: Treat the bone to cure the vessels? Kidney Int. 2006; 70: 1537-1538.
40. Phelps KR, Einhorn TA, Vigorita VJ, Lieberman PL, Uribarri J. Acidosis-induced osteomalacia: metabolic studies and skeletal histomorphometry. Bone. 1986; 7: 171-179.
41. Raggi P, James G, Burke SK, Bommer J, Chasan-Taber S, Holzer H, Braun J, Chertow GM. Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis. J Bone Miner Res. 2005; 20: 764-772.
42. Salusky IB, Foley J, Nelson P, Goodman WG. Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease. N Engl J Med. 1991; 324: 527-531.
43. Salusky IB, Goodman WG. Adynamic renal osteodystrophy: is there a problem? J Am Soc Nephrol. 2001; 12: 1978-1985.
44. Schulz E, Arfai K, Liu X, Sayre J, Gilsanz V. Aortic calcification and the risk of osteoporosis and fractures. J Clin Endocrinol Metab. 2004; 89: 4246-4253.